Moon Seong Mi, Park Hye Yun, Jeong Byeong-Ho, Jeon Kyeongman, Lee Soo-Youn, Koh Won-Jung
Division of Pulmonary and Critical Care Medicine, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea.
Department of Laboratory Medicine and Genetics, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea.
Antimicrob Agents Chemother. 2015 Jan;59(1):663-5. doi: 10.1128/AAC.04075-14. Epub 2014 Oct 13.
We investigated the effects of rifampin and rifabutin on serum itraconazole levels in patients with chronic pulmonary aspergillosis. Serum itraconazole concentrations were significantly lower in patients who received itraconazole with rifampin (median, 0.1 μg/ml; P < 0.001) or rifabutin (median, 0.34 μg/ml; P < 0.001) than those receiving itraconazole alone (median, 5.92 μg/ml). Concomitant use of rifampin or rifabutin and itraconazole should be avoided in patients with chronic pulmonary aspergillosis and coexisting mycobacterial infections.
我们研究了利福平及利福布汀对慢性肺曲霉病患者血清伊曲康唑水平的影响。接受伊曲康唑联合利福平（中位数为0.1μg/ml；P<0.001）或联合利福布汀（中位数为0.34μg/ml；P<0.001）治疗的患者，其血清伊曲康唑浓度显著低于单独接受伊曲康唑治疗的患者（中位数为5.92μg/ml）。慢性肺曲霉病合并分枝杆菌感染的患者应避免同时使用利福平或利福布汀与伊曲康唑。
